This is a working overview of GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Vehicle accidents (cars, motorcycles, bicycles, trains, etc.) Labor accidents (equipment, instruments, cylinders, chainsaws, press machines, meat machines, wood machines, etc.) Agricultural accidents, with machines and mower equipment Electric shock hazards Firearms, bladed weapons, explosives Violent rupture of ship rope or industry wire rope Ring traction (ring amputation, de-gloving injuries) Building doors and car doors Animal attacks Gas cylinder explosions Other rare accidents
=== Antimicrobial packaging === Antimicrobial packaging is designed to inhibit pathogenic or spoilage microorganisms on a product surface or within the package environment. Antimicrobial compounds may be incorporated into films and coatings, immobilised on a package surface, released into the package headspace, or contained in pads, labels, and separate emitters. Studied agents include organic acids, plant-derived compounds, enzymes, bacteriocins, metal ions, nanoparticles, and synthetic antimicrobial substances. The performance of antimicrobial packaging depends on the target microorganism, active-agent concentration, release rate, temperature, food composition, storage period, and contact between the package and the product. Absorbent pads used with meat, poultry, seafood, and fresh produce can combine liquid absorption with antimicrobial substances or freshness indicators.
=== Electronic spectrum === Electrons propagating through the graphene honeycomb lattice effectively lose their mass, producing quasi-particles described by a 2D analogue of the Dirac equation rather than the Schrödinger equation for spin-1/2 particles.
Sources: en.wikipedia.org
== External links == Peripheral membrane proteins in OPM database DOLOP Genomics-oriented database of bacterial lipoproteins Peptaibol database Archived 2011-01-27 at the Wayback Machine Antimicrobial Peptide Database Archived 2011-07-20 at the Wayback Machine
Antifreeze proteins are a perfect example of convergent evolution. Different small proteins with a flat surface which is rich in threonine from different organisms are selected to bind to the surface of ice crystals. "These include two proteins from fish, the ocean pout and the winter flounder, and three very active proteins from insects, the yellow mealworm beetle, the spruce budworm moth, and the snow flea." RNA-binding proteins which contain RNA-binding domain (RBD) and the cold-shock domain (CSD) protein family are also an example of convergent evolution. Except that they both have conserved RNP motifs, other protein sequence are totally different. However, they have a similar function. Blue-light-receptive cryptochrome expressed in the sponge eyes likely evolved convergently in the absence of opsins and nervous systems. The fully sequenced genome of Amphimedon queenslandica, a demosponge larvae, lacks one vital visual component: opsin-a gene for a light-sensitive opsin pigment which is essential for vision in other animals. The structure of immunoglobulin G-binding bacterial proteins A and H do not contain any sequences homologous to the constant repeats of IgG antibodies, but they have similar functions. Both protein G, A, H are inhibited in the interactions with IgG antibodies (IgGFc) by a synthetic peptide corresponding to an 11-amino-acid-long sequence in the COOH-terminal region of the repeats.
Krebs (1900–1981), German-British biochemist, Nobel Prize in Physiology or Medicine (1953)for work on metabolic cycles Harold Kroto (1939–2016), English chemist, 1996 Nobel Prize in Chemistry for discovery of fullerenes Richard Kuhn (1900–1967), 1938 Nobel Prize in Chemistry for work on carotenoids and vitamins Eugenia Kumacheva (PhD 1986), Ukrainian-Canadian chemist with work on fundamental and applied polymers science, nanotechnology, microfluidics, and interface chemistry Theodore Kuwana, (1931–2022), American chemist, founder of the field of spectroelectrochemistry
== Prognosis == Hypoxia caused by pulmonary fibrosis can lead to pulmonary hypertension, which in turn can lead to heart failure of the right ventricle. Hypoxia can be prevented by oxygen supplementation. Pulmonary fibrosis may also result in an increased risk of pulmonary emboli, which can be prevented by anticoagulants.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.